![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Disclaimer
The opinions expressed in this interview are those of the interviewee and do not necessarily reflect the views of Future Medicine Ltd.
Financial & competing interests disclosure
S Holdenrieder states a consultancy relationship with VolitionRX. This interview reflects his personal and independent opinion. S Holdenreider has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.
Additional information
Notes on contributors
Stefan Holdenrieder
Dr Stefan Holdenrieder speaks with Caroline Telfer, Commissioning Editor: Stefan Holdenrieder is a senior physician at the Institute of Clinical Chemistry and Clinical Pharmacology of the University Hospital Bonn (Bonn, Germany). He is an expert in the field of circulating tumor biomarkers with particular focus on circulating nucleosomes. He has conducted numerous studies concerning biomarker-based detection and monitoring of cancer diseases and has published more than 90 papers in recognized international journals.